NDAORALTABLETPriority Review
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIKAFTA is a copackaged oral combination of three small-molecule CFTR modulators (elexacaftor, tezacaftor, and ivacaftor) approved for cystic fibrosis patients with specific CFTR mutations. The triple combination addresses the underlying defect in cystic fibrosis transmembrane conductance regulator protein function. This represents a transformative approach to CF treatment by targeting the root cause rather than managing symptoms alone.
Peak11.7 years to LOE
As a peak-stage product from Vertex with robust patent protection through 2038, TRIKAFTA commands significant commercial teams and investment in market expansion, field presence, and patient support programs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
Started Nov 2016
2 enrolled
Cystic Fibrosis
Career Relevance
Working on TRIKAFTA offers exposure to a commercially mature, strategically important franchise with 272 linked career opportunities spanning medical, regulatory, and health economics disciplines. The product's peak-stage status and strong patent moat create stable, senior-level roles focused on market penetration, clinical evidence generation, and lifecycle optimization.
Director
Worked on TRIKAFTA (COPACKAGED) at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.